Newron Pharmaceuticals SpA (NWRN) Eur0.20
Sell:8.26 CHFBuy:8.64 CHF
0.05 CHF
(0.61%)
- This stock can be held in a
Stocks and Shares ISA0.05 CHF
(0.61%)0.05 CHF
(0.61%)Company Information
About this company
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Key people
Key facts
- EPICNWRN
- LocationItaly
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINIT0004147952
- Market capCHF 164.76m
- Employees23
- Shares in issue19.96m
- ExchangeSIX Swiss Exchange
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.